Matches in Nanopublications for { <http://www.w3.org/2000/01/rdf-schema#SENTENCE> ?p ?o ?g. }
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "Treatment of fibroblasts by dexamethasone increased Aminopeptidase N activity in a dose- and time-dependent manner." provenance.
- SENTENCE label "Treatment of fibroblasts by dexamethasone increased Aminopeptidase N activity in a dose- and time-dependent manner." provenance.
- SENTENCE label "Treatment of fibroblasts by dexamethasone increased Aminopeptidase N activity in a dose- and time-dependent manner." provenance.
- SENTENCE label "Treatment of fibroblasts by dexamethasone increased Aminopeptidase N activity in a dose- and time-dependent manner." provenance.
- SENTENCE label "Treatment of fibroblasts by dexamethasone increased Aminopeptidase N activity in a dose- and time-dependent manner." provenance.
- SENTENCE label "Treatment of fibroblasts by dexamethasone increased Aminopeptidase N activity in a dose- and time-dependent manner." provenance.
- SENTENCE label "glycyrrhizin (GL), as well as dexamethasone (DEX) inhibited both tumor necrosis factor (TNF)-α –and IL-1β –induced IL-8 production, mRNA expression, and promoter activity in A549 lung epithelial cells." provenance.
- SENTENCE label "glycyrrhizin (GL), as well as dexamethasone (DEX) inhibited both tumor necrosis factor (TNF)-α –and IL-1β –induced IL-8 production, mRNA expression, and promoter activity in A549 lung epithelial cells." provenance.
- SENTENCE label "To date, only dexamethasone has shown to be an effective treatment in the subgroup of patients requiring oxygen supplementation; however, countless trials including novel therapeutic approaches are ongoing." provenance.
- SENTENCE label "To date, only dexamethasone has shown to be an effective treatment in the subgroup of patients requiring oxygen supplementation; however, countless trials including novel therapeutic approaches are ongoing." provenance.
- SENTENCE label "To date, only dexamethasone has shown to be an effective treatment in the subgroup of patients requiring oxygen supplementation; however, countless trials including novel therapeutic approaches are ongoing." provenance.
- SENTENCE label "To date, only dexamethasone has shown to be an effective treatment in the subgroup of patients requiring oxygen supplementation; however, countless trials including novel therapeutic approaches are ongoing." provenance.
- SENTENCE label "To date, only dexamethasone has shown to be an effective treatment in the subgroup of patients requiring oxygen supplementation; however, countless trials including novel therapeutic approaches are ongoing." provenance.
- SENTENCE label "To date, only dexamethasone has shown to be an effective treatment in the subgroup of patients requiring oxygen supplementation; however, countless trials including novel therapeutic approaches are ongoing." provenance.
- SENTENCE label "According to the current literature We reviewed, We suggest that IFN-α and arbidol can be retained in the treatment regimen for pregnant women and that to reduce maternal mortality, appropriate doses of dexamethasone can be given to those who are predicted to have low premature survival and to receive mechanical ventilation or oxygen." provenance.
- SENTENCE label "According to the current literature We reviewed, We suggest that IFN-α and arbidol can be retained in the treatment regimen for pregnant women and that to reduce maternal mortality, appropriate doses of dexamethasone can be given to those who are predicted to have low premature survival and to receive mechanical ventilation or oxygen." provenance.
- SENTENCE label "According to the current literature We reviewed, We suggest that IFN-α and arbidol can be retained in the treatment regimen for pregnant women and that to reduce maternal mortality, appropriate doses of dexamethasone can be given to those who are predicted to have low premature survival and to receive mechanical ventilation or oxygen." provenance.
- SENTENCE label "For those of COVID-19 related pneumonia, dexamethasone and remdesivir have shown encouraging results, while vaccines are currently being evaluated in phase III trials." provenance.
- SENTENCE label "For those of COVID-19 related pneumonia, dexamethasone and remdesivir have shown encouraging results, while vaccines are currently being evaluated in phase III trials." provenance.
- SENTENCE label "For those of COVID-19 related pneumonia, dexamethasone and remdesivir have shown encouraging results, while vaccines are currently being evaluated in phase III trials." provenance.
- SENTENCE label "For those of COVID-19 related pneumonia, dexamethasone and remdesivir have shown encouraging results, while vaccines are currently being evaluated in phase III trials." provenance.
- SENTENCE label "For those of COVID-19 related pneumonia, dexamethasone and remdesivir have shown encouraging results, while vaccines are currently being evaluated in phase III trials." provenance.
- SENTENCE label "For those of COVID-19 related pneumonia, dexamethasone and remdesivir have shown encouraging results, while vaccines are currently being evaluated in phase III trials." provenance.
- SENTENCE label "For those of COVID-19 related pneumonia, dexamethasone and remdesivir have shown encouraging results, while vaccines are currently being evaluated in phase III trials." provenance.
- SENTENCE label "For those of COVID-19 related pneumonia, dexamethasone and remdesivir have shown encouraging results, while vaccines are currently being evaluated in phase III trials." provenance.
- SENTENCE label "Finally, simulations were performed to predict the antitumor efficacy of dexamethasone (DEX) combined with dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) under various dose regimens, where changing dosing frequency of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) had little effect, while the antitumor efficacy of DEX combined with SUL was predicted to be improved when dexamethasone (DEX) was given more frequently." provenance.
- SENTENCE label "Finally, simulations were performed to predict the antitumor efficacy of dexamethasone (DEX) combined with dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) under various dose regimens, where changing dosing frequency of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) had little effect, while the antitumor efficacy of DEX combined with SUL was predicted to be improved when dexamethasone (DEX) was given more frequently." provenance.
- SENTENCE label ": Early administration of dexamethasone may prevent the progression of COVID-19 to a severe disease, without increased mortality." provenance.
- SENTENCE label ": Early administration of dexamethasone may prevent the progression of COVID-19 to a severe disease, without increased mortality." provenance.
- SENTENCE label ": Early administration of dexamethasone may prevent the progression of COVID-19 to a severe disease, without increased mortality." provenance.
- SENTENCE label ": Early administration of dexamethasone may prevent the progression of COVID-19 to a severe disease, without increased mortality." provenance.
- SENTENCE label ": Early administration of dexamethasone may prevent the progression of COVID-19 to a severe disease, without increased mortality." provenance.
- SENTENCE label ": Early administration of dexamethasone may prevent the progression of COVID-19 to a severe disease, without increased mortality." provenance.
- SENTENCE label ": Early administration of dexamethasone may prevent the progression of COVID-19 to a severe disease, without increased mortality." provenance.
- SENTENCE label ": Early administration of dexamethasone may prevent the progression of COVID-19 to a severe disease, without increased mortality." provenance.
- SENTENCE label ": Early administration of dexamethasone may prevent the progression of COVID-19 to a severe disease, without increased mortality." provenance.
- SENTENCE label ": Early administration of dexamethasone may prevent the progression of COVID-19 to a severe disease, without increased mortality." provenance.
- SENTENCE label ": Early administration of dexamethasone may prevent the progression of COVID-19 to a severe disease, without increased mortality." provenance.
- SENTENCE label ": Early administration of dexamethasone may prevent the progression of COVID-19 to a severe disease, without increased mortality." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support." provenance.
- SENTENCE label "When trigeminal ganglia (TG) explants were incubated with media containing dexamethasone to stimulate reactivation, significantly fewer β-catenin+ trigeminal ganglia (TG) neurons were detected." provenance.
- SENTENCE label "When trigeminal ganglia (TG) explants were incubated with media containing dexamethasone to stimulate reactivation, significantly fewer β-catenin+ trigeminal ganglia (TG) neurons were detected." provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.